Database : MEDLINE
Search on : Patients [Words]
References found : 4039332 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 403934 go to page                         

  1 / 4039332 MEDLINE  
              next record last record
select
to print
Photocopy

[PMID]: 25480998
[Au] Autor:Bagur R; Bertrand OF; Béliveau P; Gaudreault V; Potvin JM; Fillion N; Levesque P; Tremblay B; Yadav P; Gilchrist IC
[Ad] Address:Quebec University Hospital Centre, Laval University, Quebec City, Canada. rodrigo.bagur@fmed.ulaval.ca or rodrigobagur@yahoo.com.
[Ti] Title:Feasibility of using a sheathless guiding catheter for left ventricular endomyocardial biopsy performed by transradial approach.
[So] Source:J Invasive Cardiol;26(12):E161-3, 2014 Dec.
[Is] ISSN:1557-2501
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The role of endomyocardial biopsy (EMB) in the diagnosis and treatment of adults presenting a newly unexplained cardiomyopathy remains controversial and the clinical indication varies among different centers. Furthermore, the choice of the ventricular site for EMB is still under debate. The right ventricular EMB is commonly used due to safety features and left ventricle (LV) EMB has not yet gained acceptance because of concerns about possible complications. Of note, when LV-EMB is performed, the femoral artery is usually the access site. There is a large body of evidence supporting the safety and feasibility of transradial approach in a broad spectrum of patients and settings in the catheterization laboratory. Therefore, the aim of the present manuscript is to report the feasibility of performing a LV-EMB by the transradial approach using a sheathless guiding catheter as an ad hoc procedure.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1412
[Js] Journal subset:IM
[St] Status:In-Data-Review

  2 / 4039332 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 25480997
[Au] Autor:Williams PD; Palmer S; Judkins C; Gutman J; Whitbourn R; MacIsaac A; Xu B; Burns A; Wilson A
[Ad] Address:James Cook University Hospital, Marton Road, Middlesbrough, United Kingdom TS4 3BW. dr.pdwilliams@gmail.com.
[Ti] Title:Right and Left Heart Catheterization via an Antecubital Fossa Vein and the Radial Artery - A Prospective Study.
[So] Source:J Invasive Cardiol;26(12):669-73, 2014 Dec.
[Is] ISSN:1557-2501
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Right heart catheterization has been described via the arm but previous reports have been retrospective, performed for limited indications, and may not give an accurate assessment of the success rate or safety of this technique. We sought to prospectively examine the feasibility and safety of left and right heart catheterization entirely via the arm using the radial artery and an antecubital fossa vein for a broad range of indications. Fifty-eight consecutive procedures were included. Transradial arterial access was successful in 57 patients (98%), right heart catheterization via the antecubital fossa vein was successful in 54 patients (93%) and bilateral catheterization from the arm was achieved in 53 patients (91%). Standard diagnostic catheterization was the most frequent procedure (59%), although thermodilution (6.9%), percutaneous coronary intervention (33%), and coronary sinus sampling (16%) were also performed in selected cases. Compared to a historical cohort of patients undergoing right and left heart catheterization via femoral access, mean procedural time (38 vs 47 minutes; P=.03) and screening time (8.1 vs 11.2 minutes; P<.001) were significantly reduced. There was 1 venous forearm hematoma that was managed conservatively. Right and left heart catheterization can be performed routinely via the arm in a broad range of patients and is associated with reduced procedural and fluoroscopy time as compared to femoral access. This approach can be considered for all patients in whom right and left heart catheterization is planned.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1412
[Js] Journal subset:IM
[St] Status:In-Data-Review

  3 / 4039332 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 25480995
[Au] Autor:Marggraf O; Schneppenheim S; Daubmann A; Budde U; Seiffert M; Reichenspurner H; Treede H; Blankenberg S; Diemert P
[Ad] Address:Abteilung für Allgemeine und Interventionelle Kardiologie, Universitäres Herzzentrum Hamburg, Martinistr. 52 20246 Hamburg, Germany. o.marggraf@gmx.de.
[Ti] Title:Correction of acquired von Willebrand syndrome by transcatheter aortic valve implantation.
[So] Source:J Invasive Cardiol;26(12):654-8, 2014 Dec.
[Is] ISSN:1557-2501
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:AIMS: Acquired von Willebrand syndrome (aVWS) is a common complication of severe aortic valve stenosis and can be corrected by surgical valve replacement. Transcatheter aortic valve implantation (TAVI) is gaining importance, but the influence of this new technique on aVWS has never been examined. The objective of this study was to assess the impact of TAVI on aVWS. METHODS: We enrolled 15 patients with severe aortic stenosis and high surgical risk admitted for elective TAVI. All patients were successfully treated by TAVI, using either the transfemoral (n = 6) or transapical approach (n = 9). Patients were screened for aVWS by measuring PFA-100 in vitro closure time, von Willebrand factor (VWF) antigen, VWF function, and VWF multimer analysis. Analyses were then repeated 30 minutes, 24 hours, and 7 days after valve replacement. RESULTS: Fourteen of 15 patients showed pathologic alterations of VWF. An inverse correlation was observed between the transvalvular pressure gradient and VWF high-molecular-weight multimers (VWF:HMWM) (r = -0.621; P=.01), which are essential for the platelet dependent hemostatic function of VWF. Transaortic gradient was significantly reduced in all patients following TAVI. Hemostaseologic findings improved in all patients following TAVI, the percentage of VWF:HMWM increased (19.05 ± 5.19% before TAVI to 24.08 ± 4.75% (P=.04) on day 7 post TAVI), and the multimer pattern normalized. CONCLUSIONS: Acquired von Willebrand syndrome due to aortic valve stenosis can successfully be corrected by TAVI.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1412
[Js] Journal subset:IM
[St] Status:In-Data-Review

  4 / 4039332 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 25480994
[Au] Autor:Otto S; Nitsche K; Jung C; Gassdorf J; Janiak F; Goebel B; Figulla HR; Poerner TC
[Ad] Address:1st Clinic of Medicine, Division of Cardiology, University Hospital of Jena, Germany, Erlanger Allee 101, 07747 Jena, Germany. sylvia.otto@med.uni-jena.de.
[Ti] Title:Determinants of neointimal proliferation and stent coverage after intracoronary therapy with drug-eluting devices in stable coronary artery disease: role of endothelial progenitor cells and interleukin-1 family cytokines.
[So] Source:J Invasive Cardiol;26(12):648-53, 2014 Dec.
[Is] ISSN:1557-2501
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Endothelial progenitor cells (EPCs) and cytokines seem to play a pivotal role in arterial healing after stent implantation. Using optical coherence tomography (OCT) as a high-resolution imaging technique, we aimed to assess the influence of circulating EPCs and levels of Il-1 cytokines on stent coverage and in-stent proliferation. METHODS: Eighty-nine patients were randomly treated with either Xience V drug-eluting stent (DES; n = 48) or bare-metal stent (BMS) postdilated with the SeQuent Please drug-eluting balloon (DEB; n = 41). EPC populations (CD34+/CD133+ and CD34+/CD133+/KDR+ EPC) and cytokines (Il-1ra, Il-18, and Il-1α) were measured before percutaneous coronary intervention using flow cytometry or immunoassay. Vessel remodeling was analyzed using coronary angiography and OCT at 6-month follow-up. RESULTS: Indexed neointimal volume and maximal proliferation thickness correlated inversely with EPC levels in the entire study population (r = -0.220; P=.04 and r = -0.253; P=.02) and the BMS + DEB subgroup (r = -0.344; P=.03 and r = -0.374; P=.02). Late lumen loss (LLL) was associated with the proatherogenic Il-18 concentration in the main population (r = 0.342; P=.01) and the BMS + DEB group (r = 0.471; P=.01). In the DES subgroup, associations with proliferation and LLL were lacking. Associations for stent strut coverage were not observed. CONCLUSIONS: A high EPC count seems to be a favorable individual patient factor, since it was associated with less instent proliferation. Contrarily, high Il-18 levels lead to more LLL, which emphasizes its proatherogenic properties.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1412
[Js] Journal subset:IM
[St] Status:In-Data-Review

  5 / 4039332 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 25480993
[Au] Autor:Rana O; Shah NC; Wilson S; Swallow R; O'Kane P; Levy T
[Ad] Address:Dorset Heart Centre, Royal Bournemouth Hospital, Castle Lane East, Bournemouth, BH7 7DW, United Kingdom. terry.levy@rbch.nhs.uk.
[Ti] Title:The Impact of Routine and Intravascular Ultrasound-Guided High-Pressure Postdilatation After Drug-Eluting Stent Deployment: The STent OPtimization (STOP) Study.
[So] Source:J Invasive Cardiol;26(12):640-6, 2014 Dec.
[Is] ISSN:1557-2501
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVES: Drug-eluting stent (DES) implantations with low final cross-sectional area (CSA) are associated with adverse clinical outcomes. However, there is no guidance to facilitate optimal stent deployment (SD). The stent optimization (STOP) study was performed to assess DES routine postdilatation (PD) following implantation with intravascular ultrasound (IVUS) guidance. METHODS: Forty-eight patients were included in this single-center prospective study. All DESs were deployed at 16 atm for 20 seconds and underwent routine non-compliant balloon PD (minimum 20 atm for 10 seconds). IVUS performed after SD (blinded) and PD (unblinded) measured CSA at 4 stent reference points. Optimal deployment was defined as distal and proximal stent CSA ≥60% distal and proximal reference CSA; mid and minimum stent CSA ≥70% of distal reference CSA. All per-protocol criteria were required to define optimal SD. Suboptimally deployed DESs underwent further PD with IVUS guidance (IVPD). RESULTS: Fifty-two lesions were treated in 48 patients. CSA increased by 20% following PD. STOP criteria were only achieved in 21% of DESs after SD compared to 54% after PD. IVPD was performed in 20 DESs, which increased CSA by a further 21%. STOP criteria were eventually attained in 81% cases (P<.001 for all comparisons). CONCLUSION: DES deployment leads to suboptimal deployment, which can be optimized by routine PD. IVUS identifies DES implantations that benefit from further PD. Optimizing final DES-CSA may have longterm clinical benefits, although a randomized study is required.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1412
[Js] Journal subset:IM
[St] Status:In-Data-Review

  6 / 4039332 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 25480991
[Au] Autor:Ferenc M; Kornowski R; Belardi J; Serruys P; Silber S; Widimský P; Windecker S; Neumann FJ
[Ad] Address:Universitäts- Herzzentrum Freiburg, Universitäts-Herzzentrum, Suedring 15, Bad Krozingen, 79189, Germany. Franz-Josef.Neumann@universitaets-herzzentrum.de.
[Ti] Title:Three-year outcomes of percutaneous coronary intervention with next-generation zotarolimus-eluting stents for de novo coronary bifurcation lesions.
[So] Source:J Invasive Cardiol;26(12):630-8, 2014 Dec.
[Is] ISSN:1557-2501
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:AIMS: To investigate the outcomes of percutaneous coronary intervention (PCI) in bifurcation versus non-bifurcation lesions using the next-generation Resolute zotarolimus-eluting stent (R-ZES). METHODS AND RESULTS: We analyzed 3-year pooled data from the RESOLUTE All-Comers trial and the RESOLUTE International registry. The R-ZES was used in 2772 non-bifurcation lesion patients and 703 bifurcation lesion patients, of which 482 were treated with a simple-stent technique (1 stent used to treat the bifurcation lesion) and 221 with a complex bifurcation technique (2 or more stents used). The primary endpoint was 3-year target lesion failure (TLF, defined as the composite of death from cardiac causes, target vessel myocardial infarction, or clinically-indicated target lesion revascularization [TLR]), and was 13.3% in bifurcation vs 11.3% in non-bifurcation lesion patients (adjusted P=.06). Landmark analysis revealed that this difference was driven by differences in the first 30 days between bifurcation vs non-bifurcation lesions (TLF, 6.6% vs 2.7%, respectively; adjusted P<.001), which included significant differences in each component of TLF and in-stent thrombosis. Between 31 days and 3 years, TLF, its components, and stent thrombosis did not differ significantly between bifurcation lesions and non-bifurcation lesions (TLF, 7.7% vs 9.0%, respectively; adjusted P=.50). CONCLUSION: The 3-year risk of TLF following PCI with R-ZES in bifurcation lesions was not significantly different from non-bifurcation lesions. However, there was an increased risk associated with bifurcation lesions during the first 30 days; beyond 30 days, bifurcation lesions and non-bifurcation lesions yielded similar 3-year outcomes.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1412
[Js] Journal subset:IM
[St] Status:In-Data-Review

  7 / 4039332 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 25480990
[Au] Autor:Rao Golla MS; Paul T; Rao S; Wiesen C; Yeung M; Stouffer GA
[Ad] Address:Division of Cardiology, University of North Carolina, Chapel Hill, NC 27599-7075 USA. rstouff@med.unc.edu.
[Ti] Title:Risk of developing coronary artery disease following a normal coronary angiogram in middle-aged adults.
[So] Source:J Invasive Cardiol;26(12):624-8, 2014 Dec.
[Is] ISSN:1557-2501
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Atherosclerosis begins in the teenage years and progresses over time in susceptible individuals. It is unknown, however, whether coronary angiography in middle-aged adults showing no evidence of atherosclerosis identifies individuals at low risk for subsequent development of coronary artery disease (CAD). We identified 4068 patients ≥40 years of age who had at least two coronary angiograms between January 1, 1990 and March 31, 2011. Of these, 227 patients (5.8%) had no CAD and 251 patients (6.4%) had mild atherosclerotic disease (stenosis <30%) on the initial angiogram. Patients in the normal-angiogram group were younger, more often female, and less likely to use tobacco than patients in the mild-atherosclerosis group, while rates of diabetes and hypertension were the same. Angiographic evidence of any CAD and obstructive CAD was apparent in 26% and 4.8%, respectively of the normal-angiogram group on subsequent angiography performed 75 ± 46 months later. Myocardial infarction and revascularization occurred in 4.8% and 3.5%, respectively. Progression of CAD (odds ratio = 10.2), development of obstructive CAD (odds ratio = 8.9), myocardial infarction (odds ratio = 2.7), and revascularization (odds ratio = 8.4) were more frequent in the mild-atherosclerosis group. In summary, 26% of middle-aged adults with a normal coronary angiogram who had subsequent angiography for clinical reasons developed CAD, although the annual rates of myocardial infarction or revascularization were very low. Even mild atherosclerosis on the initial angiogram increased the rate of progression of CAD by 10-fold and the rate of revascularization by 8-fold.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1412
[Js] Journal subset:IM
[St] Status:In-Data-Review

  8 / 4039332 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 25480989
[Au] Autor:Meelu OA; Tomey MI; Sartori S; Kherada N; Mennuni MG; Theodoropoulos KN; Sayeneni S; Baber U; Pyo RT; Kovacic JC; Moreno P; Krishnan P; Mehran R; Dangas GD; Kini AS; Sharma SK
[Ad] Address:Mount Sinai School of Medicine, New York, New York. roxana.mehran@mssm.edu.
[Ti] Title:Comparison of Provisional 1-Stent and 2-Stent Strategies in Diabetic Patients With True Bifurcation Lesions: The EES Bifurcation Study.
[So] Source:J Invasive Cardiol;26(12):619-23, 2014 Dec.
[Is] ISSN:1557-2501
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Percutaneous coronary intervention (PCI) of true bifurcation lesions (Medina classification 1, 1, 1; 1, 0, 1; or 0, 1, 1) is challenging and may involve either a 1-stent strategy with provisional side branch stenting, or a 2-stent strategy. Diabetes mellitus is associated with greater atherosclerotic burden and higher incidence of bifurcation lesions, and unfavorable outcomes after PCI. It is unknown whether use of newer everolimus-eluting stent (EES) implantation impacts relative outcomes of 1-stent and 2-stent strategies in patients with diabetes. METHODS: We performed a retrospective analysis of consecutive patients with diabetes mellitus and complex true bifurcation lesions (side branch diameter >2.0 mm) who underwent PCI with EES between February 2010 and December 2011. We grouped subjects based on initial treatment to a 1-stent (n = 81) or 2-stent (n = 54) strategy, and compared baseline characteristics, quantitative coronary angiography, and 1-year major adverse cardiovascular event (MACE) rates, defined as death, myocardial infarction, target lesion revascularization (TLR), or target vessel revascularization (TVR). RESULTS: Baseline characteristics were well matched. A 2-stent strategy was associated with larger side-branch reference vessel diameter at baseline and post PCI. In-hospital events included 1 periprocedural myocardial infarction in each group and no deaths. At 1 year, there was no significant difference between 1-stent and 2-stent strategies in TVR rates (6.2% vs 3.7%; P=.53), TLR (both 3.7%; P>.99), or MACE (7.4% vs 3.7%; P=.37). CONCLUSION: In this series of diabetic patients undergoing complex bifurcation PCI using EES implantation, there was no difference between 1-stent and 2-stent strategies with respect to ischemic events at 1 year.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1412
[Js] Journal subset:IM
[St] Status:In-Data-Review

  9 / 4039332 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25253784
[Au] Autor:Ganesan P; Moulder S; Lee JJ; Janku F; Valero V; Zinner RG; Naing A; Fu S; Tsimberidou AM; Hong D; Stephen B; Stephens P; Yelensky R; Meric-Bernstam F; Kurzrock R; Wheler JJ
[Ad] Address:Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas....
[Ti] Title:Triple-negative breast cancer patients treated at MD anderson cancer center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.
[So] Source:Mol Cancer Ther;13(12):3175-84, 2014 Dec.
[Is] ISSN:1538-8514
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Patients with metastatic triple-negative breast cancer (TNBC) have poor treatment outcomes. We reviewed the electronic records of consecutive patients with metastatic TNBC treated in phase I clinic at MD Anderson Cancer Center (Houston, TX) between Augu st 2005 and May 2012. One hundred and six patients received at least 1 phase I trial. Twelve of 98 evaluable patients (12%) had either complete response (CR; n = 1), partial response (PR; n = 7), or stable disease ≥6 months (SD; n = 4). Patients treated on matched therapy (n = 16) compared with those on nonmatched therapy (n = 90) had improved SD ≥ 6 months/PR/CR (33% vs. 8%; P = 0.018) and longer progression-free survival (PFS; median, 6.4 vs. 1.9 months; P = 0.001). Eleven of 57 evaluable patients (19%) treated with combination chemotherapy and targeted therapy had SD ≥ 6 months/PR/CR versus 1 of 41 evaluable patients (2%) treated on other phase I trials (P = 0.013), and longer PFS (3.0 vs. 1.6 months; P < 0.0001). Patients with molecular alterations in the PI3K/AKT/mTOR pathway treated on matched therapy (n = 16) had improved PFS compared with those with and without molecular alterations treated on nonmatched therapy (n = 27; 6.4 vs. 3.2 months; P = 0.036). On multivariate analysis, improved PFS was associated with treatment with combined chemotherapy and targeted agents (P = 0.0002), ≤2 metastatic sites (P = 0.003), therapy with PI3K/AKT/mTOR inhibitors for those with cognate pathway abnormalities (P = 0.018), and treatment with antiangiogenic agents (P = 0.023). In summary, combinations of chemotherapy and angiogenesis and/or PI3K/AKT/mTOR inhibitors demonstrated improved outcomes in patients with metastatic TNBC. Mol Cancer Ther; 13(12); 3175-84. ©2014 AACR.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1412
[Cu] Class update date: 141206
[Lr] Last revision date:141206
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1158/1535-7163.MCT-14-0358

  10 / 4039332 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 25249556
[Au] Autor:Yu G; Yao W; Gumireddy K; Li A; Wang J; Xiao W; Chen K; Xiao H; Li H; Tang K; Ye Z; Huang Q; Xu H
[Ad] Address:Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China....
[Ti] Title:Pseudogene PTENP1 Functions as a Competing Endogenous RNA to Suppress Clear-Cell Renal Cell Carcinoma Progression.
[So] Source:Mol Cancer Ther;13(12):3086-97, 2014 Dec.
[Is] ISSN:1538-8514
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PTENP1 is a pseudogene of the PTEN tumor suppression gene (TSG). The functions of PTENP1 in clear-cell renal cell carcinoma (ccRCC) have not yet been studied. We found that PTENP1 is downregulated in ccRCC tissues and cells due to methylation. PTENP1 and PTEN are direct targets of miRNA miR21 and their expression is suppressed by miR21 in ccRCC cell lines. miR21 expression promotes ccRCC cell proliferation, migration, invasion in vitro, and tumor growth and metastasis in vivo. Overexpression of PTENP1 in cells expressing miR21 reduces cell proliferation, invasion, tumor growth, and metastasis, recapitulating the phenotypes induced by PTEN expression. Overexpression of PTENP1 in ccRCC cells sensitizes these cells to cisplatin and gemcitabine treatments in vitro and in vivo. In clinical samples, the expression of PTENP1 and PTEN is correlated, and both expressions are inversely correlated with miR21 expression. Patients with ccRCC with no PTENP1 expression have a lower survival rate. These results suggest that PTENP1 functions as a competing endogenous RNA (ceRNA) in ccRCC to suppress cancer progression. Mol Cancer Ther; 13(12); 3086-97. ©2014 AACR.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1412
[Cu] Class update date: 141206
[Lr] Last revision date:141206
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1158/1535-7163.MCT-14-0245


page 1 of 403934 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information